Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vimpat (lacosamide) C-V, a new antiepileptic drug (AED) will be available in the US from the first week of June. FDA had approved the drug in the fall of 2008, to be used as an add on therapy for the treatment of partial onset seizures in people 17 years and older with epilepsy.
Subscribe to our email newsletter
FDA approval was based on safety and efficacy data from three pivotal trials with approximately 1,300 patients. The study demonstrated, patients taking Vimpat had their seizures reduced to half or more and experienced reductions in median seizure frequency compared to those in the placebo group. Vimpat demonstrated efficacy and safety when combined with a broad range of existing AEDs.
Vimpat is available in 50mg, 100mg, 150mg, and 200 mg strengths and as an IV infusion.